Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
Clinical trial NCT00291473 · COMPLETED
Trial details
- NCT number
- NCT00291473
- Sponsor
- Ludwig Institute for Cancer Research
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2005-07-01
- Primary completion
- 2008-08-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.